The data have been obtained from the Sigma-2 Receptor Selective Ligands Database (S2RSLDB) and refined according to the QSAR requirements. These data provide information about a set of 548 Sigma-2 (σ 2 ) receptor ligands selective over Sigma-1 (σ 1 ) receptor. The development of the QSAR model has been undertaken with the use of CORAL software using SMILES, molecular graphs and hybrid descriptors (SMILES and graph together). Data here reported include the regression for σ 2 receptor pK i QSAR models. The QSAR model was also employed to predict the σ 2 receptor pK i values of the FDA approved drugs that are herewith included.
Data
The sigma-2 (σ 2 ) receptor is a peculiar target overexpressed in several tumor cell lines and its ligands are actually under clinical evaluation as positron emission tomography radiotracer and as fluorescence imaging agents [1] [2] [3] . Few selective ligands have been found for the σ 2 receptor and in some cases, their finding occurred through an accidental discovery [1, 4] . Data here reported provide information about a set of σ 2 receptor ligands, taken from the Sigma-2 Receptor Selective Ligands Database (S2RSLDB), and selective over σ 1 receptor, together with their pK i (-logK i ) [5] . These latter have been used in building up the first hybrid QSAR model embracing the all set of known σ 2 receptor selective ligands [6] . The model has also been used to predict the σ 2 receptor pK i for the Food and Drug Administration approved drugs. These latter predicted σ 2 receptor pK i data are also here reported. T * and N * are preferable values for the threshold and the number of epochs, respectively; n is the number of compounds in the set; r 2 is the correlation coefficient; q 2 is the cross-validated correlation coefficient; s is the root-mean-square error; F is the Fisher F ratio; F (0.05,1,n-2) is the 0.05-quantile of the Fisher's distribution F (1,n-2) ; p-value is the Fisher test's significance level.
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Dataset preparation
The dataset consists of 548 σ 2 receptor selective ligands which were randomly split three times and then divided into training (209 compounds), invisible training (209 compounds), calibration (65 compounds) sets for model development and a validation set (65 compounds) for invisible model validation. The three splits and four sets have been randomly generated, and their pK i minimum, maximum and middle are reported in Table 1 .
QSAR model development
QSAR models have been developed with the use of the software CORAL [7] . Once the splits and sets were determined, nine models were developed and statistical quality recorded. Differences of these models consist in the way molecular structures have been depicted the software. Thus, in Table 2 regressions for the σ 2 receptor pK i models using SMILES, molecular graphs and hybrid descriptors (SMILES and graph together) are reported. While in Table 3 is reported the statistical quality of models of the σ 2 receptor pK i . Fig. 1 shows a CORAL screenshot with settings for hybrid model split 1. While in Table 4 , the complete list of SMILES and their distribution into the sub-training ( þ), calibration (-), test (#) and validation (*) sets for σ 2 receptor pK i hybrid model split 1 is reported. These data may be prospectively used in finding novel models for σ 2 receptor affinity. 
QSAR model settings for the best model [hybrid model split 1]

Table 4
List of SMILES and their distribution into the sub-training ( þ), calibration (-), test (#) and validation (*) for hybrid model split 1. Table 5 List of SMILES and predicted pK i of the FDA-approved drugs. 
QSAR Hybrid model split 1 validation
The endpoints of the FDA-approved drugs were determined in order to additionally validate the model. The whole set composed of 1428 drugs was refined in order to remove quaternary ammonium salts, and compounds with too long SMILES (not elaborated by CORAL), and compounds containing atoms not enumerated in the model (Al, Fe, Gd, etc.) . Overall, the whole set was reduced to 1376 compounds and these were evaluated with hybrid model resulting from split 1. Over 1376 compounds, 925 have been defined as outliers by the model since they fall outside the domain of applicability. Table 5 reports the SMILES and predicted σ 2 pK i for these FDA approved drugs evaluated with the hybrid model split 1.
